Jennifer Edelman, MD, MHS | Department of Internal Medicine, Yale University School of Medicine
Jeanette M. Tetrault, MD, FACP | Department of Internal Medicine, Yale University School of Medicine
The October 22nd webinar addressed questions and comments from participants of the live webinar, which took place on September 10, 2015, and those taken on the day of the 10/22 session. Drs. Tetrault and Edelman also presented a few cases in relation to their topic.
The September 10th webinar highlighted that people with opioid use disorders are commonly infected with Hepatitis C virus (HCV) and/or HIV. It is important that all providers delivering treatment to individuals with opioid use disorders understand appropriate prevention, screening and treatment strategies of HCV and HIV and specific considerations for people receiving opioid agonist therapy. The discussion included an understanding of the latest technology used for detection of HCV and HIV, appropriate use of highly effective antiviral therapy, and recognition of potential interactions with methadone, buprenorphine and naltrexone. A strong foundation in understanding HCV and HIV prevention and treatment strategies is important for all providers treating individuals with opioid use disorders. Click HERE to complete the archived September 10th webinar.
- Recognize screening and testing strategies for HCV and HIV;
- Discuss the natural history and transmission risk of HCV and HIV;
- Describe HCV and HIV prevention strategies; and
- Review current treatment approaches for HCV and HIV and recognize important treatment considerations
PC-based attendees Required: Windows® 8, 7, Vista, XP or 2003 Server
Mac®-based attendees Required: Mac OS® X 10